Title: Low-dose irradiation for controlling prostate cancer

Authors: Jerry M. Cuttler

Addresses: Cuttler & Associates Inc., 1781 Medallion Court, Mississauga, Ontario L5J 2L6, Canada

Abstract: Prostate cancer is the second most commonly diagnosed cancer among North American men and the second leading cause of death in those aged 65 and over. The US Cancer Society recommends testing those over 50 years of age who are expected to live at least for 10 years, even though the ability of early detection to decrease prostate cancer mortality has not been demonstrated. A controversy exists about the appropriateness of screening because of the considerable economic and social burden of diagnosing and treating prostate cancer, coupled with the projected large increase in the number of new cases as the population ages. This very important public health issue could be addressed at low cost by total-body low-dose irradiation therapy to stimulate the patient|s own defences to prevent and control most cancers, including prostate cancer, with no symptomatic side effects.

Keywords: prostate cancer; low-dose irradiation; stimulation; defences; prophylaxis; cure; low radiation; whole body irradiation; irradiation therapy.

DOI: 10.1504/IJLR.2006.007895

International Journal of Low Radiation, 2006 Vol.2 No.1/2, pp.45 - 59

Published online: 30 Sep 2005 *

Full-text access for editors Full-text access for subscribers Purchase this article Comment on this article